Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Get a window into what the leading players across the biopharma, medtech, and diagnostics industries are thinking, as well as important insight into what your competitors are doing. Build your strategy with In Vivo.
Construct winning strategies that anticipate where value will lie. In Vivo’s in-depth analysis spans influential deals, R&D, commercial and market access strategies.
How it helps
With In Vivo, you’ll benefit from:
How it works
Access mission-critical information via a simple-to-use interface. And if you need to need to find out more about developments or pharmaceutical industry trends to support presentations, proposals or business-critical decisions, you can access our worldwide network of expert analysts through our acclaimed Ask-the-Analyst™ service.
Plus, you can identify threats and opportunities using our Execs on the Move feature, which tracks the company movements of senior executives.
In Vivo
Power your strongest strategy for the year ahead with insights from the Outlook 2021 report. A combination of Scrip’s Scrip 100, Medtech Insight’s Medtech 100, and In Vivo’s Outlook reports, Outlook 2021 is a comprehensive window into the key trends, challenges and opportunities impacting the biopharma, medtech, and generics sectors for the year to come.
Topic Outlook
In Vivo
The COVID-19 pandemic is disrupting global supply chains and companies need effective tools to manage the related contract disputes. Sidley Austin partner Dorothee Schramm and senior associate Katie von der Weid, both specialized in international commercial disputes, provide tips to help companies manage the situation.
In Vivo
In today’s globalized market for medicines, national rules on pricing and access are abundantly shared and more transparent than opaque. In Vivo speaks to the UK branded industry’s negotiator for the latest five-year joint pricing pact with the government, Richard Torbett, who outlines, among other topics, five widely applicable precedents from the talks that can work in “getting to yes” – despite the fractious budgetary climate for health care evident in all major country markets.
Topic Brexit Policy & Regulation
In Vivo
Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.
In Vivo
FDA guidance updated in mid-April offered workarounds for trial sponsors attempting to conduct clinical studies in a time of travel limitations, staffing changes and heightened patient safety issues. For trials involving complex products and administration, such as cell and gene therapies, sponsors must determine whether modified protocols can still maintain trial integrity. If not, it may be time to press pause.
Topic Coronavirus FDA
In Vivo
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.
In Vivo
Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D.
Topic Coronavirus Vaccines
In Vivo
Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.
In Vivo
Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.
In Vivo
Immuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative work and shaky hypotheses—overshadowing other pursuits in cancer research while producing limited results. It is time to re-evaluate how the sector should be pursuing innovation in cancer and how it can be smarter in its use of resources—financial investment, talent, bandwidth, patients and data.
Topic Cancer Research & Development
In Vivo, Medtech Insight
Join distinguished cancer and industry experts as they explore what a shift in cancer treatment – from late stage intervention to an early detection paradigm – would mean for patient outcomes, cancer costs, technology, development, regulatory affairs, and more. Explore this new approach toward focusing on early stage cancer detection, including discussion of diagnostics in this area, such as biomarker identification, liquid biopsies, and monitoring technologies.
Topic Diagnostics Cancer
In Vivo, Scrip
2020 coverage from Scrip and In Vivo provides rich insights into the attitudes and trends around deals and financing, two major engines of innovation and growth for biopharma during this current pandemic period.
In Vivo, Medtech Insight, Pink Sheet, Scrip
Explore how digital technologies are being used to address the disruption of clinical trials for drugs and medical technology caused by COVID-19. Stay current with insights from industry leaders, information on guidance and regulation, and an examination of how the challenges of this global crisis and the industry’s response to it may soon usher in a new era in worldwide healthcare.
Topic Coronavirus
In Vivo
As night turned to day on June 24, it became clearer by the hour that the unthinkable had happened, and the UK’s long and acrimonious debate about its 43-year membership of the European Union had ended in a victory for the Leave group. The local health care products industries made their views clear some weeks ago, but today and in the months to come, they will have to confront a Plan B that was never in the plans.
Topic Market Access Brexit
Pink Sheet, Scrip, In Vivo
Keep up with advances in the critically important, emerging area of gene therapy. This transformative new category of medicines has the potential to treat more diseases – including complex and rare diseases – with longer-lasting effects than traditional medicines.
Topic Research & Development Deals
In Vivo
20 Jan 2021
In Vivo
20 Jan 2021
In Vivo
20 Jan 2021
In Vivo
18 Jan 2021
In Vivo
18 Jan 2021
In Vivo
14 Jan 2021
In Vivo
14 Jan 2021
In Vivo
14 Jan 2021
In Vivo
12 Jan 2021
In Vivo
12 Jan 2021
In Vivo
12 Jan 2021
In Vivo
06 Jan 2021
In Vivo
06 Jan 2021
In Vivo
06 Jan 2021
In Vivo
04 Jan 2021
USA
William specializes in
+40 year(s) experience
Washington DC, USA
Cathy specializes in
+39 year(s) experience
Washington DC, USA
Denise specializes in
+38 year(s) experience
Support the development and validation of your strategic plans and ensure commercial decisions are based on marketplace realities. Datamonitor Healthcare offers expert coverage of key diseases, treatments, companies, drugs, market access and market trends. Our primary research with physicians, payers, and KOLs (key opinion leaders) informs our treatment standards data and patient-based forecasts.
You’ll instantly connect to the latest in global medtech developments with industry news, trends, deals, product developments, opinions, analysis, and context behind the headlines and more – all available at your fingertips.
In the continually evolving medtech competitive landscape, it is vital to stay up-to-date with key events. With Meddevicetracker, you’ll be able to anticipate upcoming filings, research clinical trial dates and data, and access market size information and expert forecasts, all in one place.
Looking for more products Product Finder
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
